Literature DB >> 16267411

Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients.

Darleen R Powars1, Linda S Chan, Alan Hiti, Emily Ramicone, Cage Johnson.   

Abstract

Based on a prospective cohort study of 1056 patients with sickle cell anemia (Hb SS) initiated in 1959, we investigated the influence of calendar era, age, sex, and prior medical conditions on the subsequent development of irreversible organ damage and survival using the Cox regression model with time-dependent covariates adjusting for all prior occurrences. We studied 30 acute clinical events, and focused on 8 prototypic forms of irreversible organ damage. Childhood survival to age 20 years has improved from 79% for those born before 1975 to 89% for children born in or after 1975. Bone infarction was a significant risk factor for avascular necrosis (p = 0.01), and infantile dactylitis was a significant risk factor for stroke (p = 0.01). Prior hospitalized vaso-occlusive sickle crisis in adults was significantly associated with the increased rate of avascular necrosis (p < 0.001), leg ulcers (p < 0.001), sickle chronic lung disease (p < 0.001), renal failure (p < 0.005), and early death (p < 0.001). The diagnosis of clearly evident clinical conditions such as leg ulcer, osteonecrosis, and retinopathy predicted an increased likelihood of developing a more lethal form of organ damage and earlier death: 77% of patients with chronic lung disease, 75% of those with renal insufficiency, and 51% of those with stroke had a prior chronic condition. Of the 232 patients who died, 73% had 1 or more clinically recognized forms of irreversible organ damage. By the fifth decade, nearly one-half of the surviving patients (48%) had documented irreversible organ damage. End-stage renal disease (glomerulosclerosis), chronic pulmonary disease with pulmonary hypertension, retinopathy, and cerebral microinfarctions are manifestations of arterial and capillary microcirculation obstructive vasculopathy. The current study underscores the need for preventive therapy to ameliorate the progression of the sickle vasculopathy.

Entities:  

Mesh:

Year:  2005        PMID: 16267411     DOI: 10.1097/01.md.0000189089.45003.52

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  188 in total

Review 1.  The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease.

Authors:  John J Strouse; Sophie Lanzkron; Victor Urrutia
Journal:  Expert Rev Hematol       Date:  2011-12       Impact factor: 2.929

2.  Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes.

Authors:  Carlton D Dampier; Wally R Smith; Hae-Young Kim; Carrie Greene Wager; Margaret C Bell; Caterina P Minniti; Jeffrey Keefer; Lewis Hsu; Lakshmanan Krishnamurti; A Kyle Mack; Donna McClish; Sonja M McKinlay; Scott T Miller; Ifeyinwa Osunkwo; Phillip Seaman; Marilyn J Telen; Debra L Weiner
Journal:  Am J Hematol       Date:  2011-09-22       Impact factor: 10.047

3.  Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease.

Authors:  Lauren J Becton; Ram V Kalpatthi; Elizabeth Rackoff; Deborah Disco; John K Orak; Sherron M Jackson; Ibrahim F Shatat
Journal:  Pediatr Nephrol       Date:  2010-05-27       Impact factor: 3.714

4.  Reproductive health choices for young adults with sickle cell disease or trait: randomized controlled trial immediate posttest effects.

Authors:  Diana J Wilkie; Agatha M Gallo; Yingwei Yao; Robert E Molokie; Christine Stahl; Patricia E Hershberger; Zhongsheng Zhao; Marie L Suarez; Robert J Labotka; Bonnye Johnson; Rigo Angulo; Veronica Angulo; Jesus Carrasco; David Shuey; Stephanie Pelligra; Edward Wang; Dennie T Rogers; Alexis A Thompson
Journal:  Nurs Res       Date:  2013 Sep-Oct       Impact factor: 2.381

5.  Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia.

Authors:  Santosh L Saraf; Xu Zhang; Tamir Kanias; James P Lash; Robert E Molokie; Bharvi Oza; Catherine Lai; Julie H Rowe; Michel Gowhari; Johara Hassan; Joseph Desimone; Roberto F Machado; Mark T Gladwin; Jane A Little; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2013-12-12       Impact factor: 6.998

6.  Health care provider attitudes toward patients with acute vaso-occlusive crisis due to sickle cell disease: development of a scale.

Authors:  Neda Ratanawongsa; Carlton Haywood; Shawn M Bediako; Lakshmi Lattimer; Sophie Lanzkron; Peter M Hill; Neil R Powe; Mary Catherine Beach
Journal:  Patient Educ Couns       Date:  2009-02-23

Review 7.  Leg Ulcers in Sickle-Cell Disease: Treatment Update.

Authors:  Jean-Benoît Monfort; Patricia Senet
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-04-24       Impact factor: 4.730

8.  Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.

Authors:  Omar Niss; Adam Lane; Monika R Asnani; Marianne E Yee; Ashok Raj; Susan Creary; Courtney Fitzhugh; Prasad Bodas; Santosh L Saraf; Sharada Sarnaik; Prasad Devarajan; Punam Malik
Journal:  Blood Adv       Date:  2020-04-14

9.  Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.

Authors:  Matthew M Hsieh; Elizabeth M Kang; Courtney D Fitzhugh; M Beth Link; Charles D Bolan; Roger Kurlander; Richard W Childs; Griffin P Rodgers; Jonathan D Powell; John F Tisdale
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

10.  Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study.

Authors:  Mehdi Nouraie; Deepika S Darbari; Sohail Rana; Caterina P Minniti; Oswaldo L Castro; Lori Luchtman-Jones; Craig Sable; Niti Dham; Gregory J Kato; Mark T Gladwin; Gregory Ensing; Manuel Arteta; Andrew Campbell; James G Taylor; Sergei Nekhai; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2020-04-21       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.